BLAINJECTIONINJECTABLE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs) by Roche is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2024.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TECENTRIQ HYBREZA is a PD-1 blocking monoclonal antibody (atezolizumab) formulated with hyaluronidase (TQJS) for subcutaneous injection, enabling at-home or clinic-based administration. It harnesses immune checkpoint inhibition to restore T-cell-mediated anti-tumor immunity. The hyaluronidase component allows rapid subcutaneous delivery of the full antibody dose, improving convenience versus intravenous administration.
Growth
Recent 2024 approval positions this as a growth-stage asset with expanding market penetration; teams will focus on launch acceleration, payer access, and patient adoption strategies.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TECENTRIQ HYBREZA represents a high-visibility launch in oncology immunotherapy with differentiated subcutaneous delivery; roles on this team involve shaping market adoption, managing payer negotiations, and driving clinical evidence generation in a competitive landscape. Career growth is supported by the product's growth-stage lifecycle and the strategic importance of checkpoint inhibitors to Roche's oncology portfolio.
Brand Manager
Worked on TECENTRIQ HYBREZA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.